U.S. Markets closed

Cytosorbents Corporation (CTSO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.90+0.12 (+1.37%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.78
Open8.82
Bid8.63 x 3200
Ask9.05 x 800
Day's Range8.73 - 8.94
52 Week Range6.07 - 11.74
Volume107,806
Avg. Volume364,193
Market Cap385.048M
Beta (5Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateMar 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.75
  • CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey
    PR Newswire

    CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the lease of its new global headquarters in Princeton, NJ. On March, 26, 2021, the company entered into a new agreement with National Business Parks to lease approximately 48,500 square feet located at 305 College Road East at Princeton Forrestal Village in Princeton, New Jersey. The mixed-use facility is expected to accommodate all U.S. administrative, clinical, commercialization, manufacturing, and research and development activities. The 15-year lease is expected to commence on June 1, 2021, subject to certain conditions.

  • CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery
    PR Newswire

    CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery

    CytoSorbents Corporation (NASDAQ: CTSO) announces the filing of an Investigational Device Exemption (IDE) application to conduct the clinical study, "Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)," in the United States to support an initial FDA regulatory approval. This is being done under the previously announced FDA Breakthrough Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit during urgent and emergent cardiac surgery.

  • CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference
    PR Newswire

    CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Oppenheimer 31st Annual Healthcare Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD will present an overview of the Company's progress and outlook. Company management will also meet with investors in 1x1 meetings throughout the day. To schedule a meeting with management, please contact your Oppenheimer representative.